

Molecular cloning and characterization of a full-length cDNA clone for human plasminogen

Margaretha Forsgren, Benny Råden, Marianne Israelsson, Kerstin Larsson and Lars-Olof Hedén

KabiGen AB, Department of Molecular Biology, S-112 87 Stockholm, Sweden

Received 9 January 1987

A human liver cDNA library enriched for full-length clones was screened for plasminogen cDNA using a synthetic 24-nucleotide probe derived from a reported partial cDNA sequence. 12 positive clones were identified and one of these was characterized in detail. The 2.7 kb insert contains the complete coding region. At 5 positions, it gives residues different from those reported in a previous amino acid sequence analysis of the protein. The present results show an extra Ile at position 65, Gln instead of Glu at positions 53 and 342, Asn at position 88 instead of Asp, and Asp at position 453 rather than Asn. In the 3'-non-coding region an extension of 29 bases is found which does not contain any structure compatible with a known polyadenylation signal. Instead, the consensus signal AATAAA is placed at a distance of 46 bases upstream of the poly(A)-tail.

cDNA; Plasminogen; Plasma protein; (Human)

1. INTRODUCTION

The glycoprotein plasminogen is a zymogen involved in the final steps of fibrinolysis [1]. The amino acid sequence of human plasminogen has been determined [2–5]. The one-chain proenzyme is converted to the active two-chain molecule plasmin by cleavage of the peptide bond between Arg-560 and Val-561 [6]. This specific cleavage is mediated by plasminogen activators, e.g. tissue plasminogen activator and urokinase. The serine protease function of the molecule is located in the carboxy-terminal part of the original protein (giving the light chain after the activation cleavage). This region shows considerable amino acid sequence homology with the serine proteases involved in blood coagulation, as well as those involved in other physiological processes such as the digestive enzymes of the pancreas.

In the amino terminal part of the original molecule (the heavy chain) five tandem repeats, called kringles, are present. These structures, containing about 80 amino acids each are homologous to the two kringles present in the amino-terminal region of tissue plasminogen activator and prothrombin, as well as the single kringle present in the amino-terminal portion of urokinase and factor XII of the blood coagulation (review [7]). The exact role of the kringles has not yet been elucidated, but at least in plasminogen and prothrombin some of the kringles have been shown to mediate fibrin binding.

Based on the amino acid sequence homology between the serine proteases of coagulation and fibrinolysis Patthy [7,8] among others has proposed a hypothesis for the evolution of these enzymes based on the assumption of exon-shuffling. To allow a more thorough and stringent comparison of the different domains in these proteins knowledge of the complete nucleotide sequences of the respective genes and their genomic organization is essential.

Correspondence address: L.-O. Hedén, University of Lund, Dept of Microbiology, S-223 62 Lund, Sweden

Plasminogen, and many other enzymes in the coagulation and fibrinolysis systems, are synthesized in the liver. Recently a partial cDNA clone for plasminogen from human liver mRNA has been described [9]. In the present communication, a full-length cDNA clone for human plasminogen is reported.

2. MATERIALS AND METHODS

2.1. Restriction enzymes and isotopes

Restriction enzymes, [α - 35 S]dCTP (1100 Ci/mmol), and [γ - 32 P]ATP (3000 Ci/mmol) were obtained from Amersham.

2.2. Construction and isolation of cDNA clones

In order to increase the probability to isolate a full-length cDNA clone for plasminogen, the method described by Okayama and Berg [10,11] was used with some modifications. The vector and linker fragments were both prepared from the plasmid pT₄ (kindly provided by G. Gross, Gesellschaft für Biotechnologische Forschung, Braunschweig) as described in fig.1. The use of the plasmid pT₄ in preparing cDNA libraries has a great advantage in that the same vector can be used in the preparations of the vector and linker fragments, and inserts can easily be cleaved out. Some 10 bp downstream of the *Kpn*I site there is a unique *Pst*I site. Preparation of the linker fragment as outlined in fig.1 will recreate the *Kpn*I site. From 1 μ g vector DNA and 5 μ g human liver mRNA about 1.5×10^5 transformants were obtained. The transformants were pooled and frozen in glycerol at -70°C . From the published partial cDNA sequence [9], a 24-nucleotide probe was synthesized [12] and labelled with [32 P]ATP as described [13].

2.3. Plasmid DNA preparation and restriction enzyme analysis

Plasmid DNA was isolated by density gradient centrifugation of cleared lysates [13] or by preparation of minilysates [14]. Restriction enzyme analysis of plasmid DNA was done as described [13].

Agarose gel electrophoresis was done in 0.8% DNA grade agarose (Bio-Rad Laboratories) in Tris-acetate buffer [13], 100 V, at room




Fig.1. Schematic description of the vector pT₄ and the preparation of vector and linker fragments for cDNA cloning according to the Okayama-Berg procedure [10,11]. Only restriction enzyme sites relevant to the text are indicated.

temperature. Low gelling temperature agarose gels were run in the same buffer at $+4^\circ\text{C}$.

Transfer of restriction DNA fragments separated on agarose gel to nitrocellulose filter for hybridization was done by the Southern procedure [13].

2.4. Nucleotide sequence determination

Nucleotide sequence determination was done by the Sanger dideoxy chain-termination method [15] using ^{35}S -labelled dCTP. Subcloning of appropriate restriction enzyme fragments in M13mp18 and M13mp19 was done by separating the DNA fragments on a 0.8% low gelling temperature agarose gel (Bio-Rad Laboratories) and subsequent ligation to the vectors as described

Table 1

Oligonucleotide probe derived from the partial cDNA sequence [9] for the screening of the cDNA library

	292							299	
Amino acid sequence	Ser-	Gly-	His-	Thr-	Cys-	Gln-	His-	Trp	
DNA sequence	5'- TCC	GGG	CAC	ACC	TGT	CAG	CAC	TGG	-3'
	3'- AGG	CCC	GTG	TGG	ACA	GTC	GTG	ACC	-5'
DNA probe	5'- TCC	GGG	CAC	ACC	TGT	CAG	CAC	TGG	-3'

The amino acid numbers given are with reference to the sequence in fig.4

by Crouse et al. [16]. For confirmation of the DNA sequence around the restriction enzyme sites used in the subcloning, synthetic oligonucleotide primers were used.

3. RESULTS

About 10000 transformants in the human liver cDNA library were screened for plasminogen cDNA using a 32 P-labelled oligonucleotide probe (see table 1 for the sequence). Twelve positive

clones were identified and, after rescreening, minilysates were analysed by agarose gel electrophoresis. One of the clones was chosen for a detailed analysis. An initial restriction enzyme analysis of plasmid DNA from this clone showed the size of the insert to be about 2.7 kb (fig.2A) which is a size expected for a full-length clone. Southern analysis (fig.2B) and DNA sequencing of fragments hybridizing to the oligonucleotide probe confirmed the presence of a plasminogen coding sequence. For the complete nucleotide sequence




Fig.2. Restriction enzyme analysis and Southern analysis of the human plasminogen cDNA clone pPLGKG. Lanes 1 and 8, pBR322 digested with *Hinf*I as a molecular size marker. Lanes 2-7: pPLGKG digested with *Eco*RI (lane 2), *Bam*HI (3), *Kpn*I and *Pst*I (4), *Pst*I (5), *Kpn*I (6), and *Hind*III (7). (A) Ethidium bromide staining and (B) autoradiogram after hybridization with the DNA probe used for the colony hybridization.




Fig.3. Partial restriction enzyme map for the human plasminogen cDNA clone pPLGKG. Only restriction enzyme sites used in the DNA sequence determination are shown. The boxed region shows the coding part. The arrows represent subcloned fragments and the direction of the sequence determination. $\circ \rightarrow$ represents synthetic primers.

determination, restriction enzyme fragments were subcloned in M13 as outlined in fig.3. The DNA sequence was determined on both strands. For the 5'-*KpnI-EcoRI* and the 3'-*TaqI-PstI* fragments internal synthetic oligonucleotide primers were used due to difficulties determining the sequence over the G/C and A/T tails.

In fig.4 the complete nucleotide sequence is presented. A 5'-non-coding region of 64 bp is present and as most eukaryotic mRNA usually have a 5'-non-coding region ranging from 40 to 80 nucleotides [17] this indicates that the clone obtained may be of full length. The 253 bp 3'-non-coding region is an extension by 29 bp in comparison to the partial cDNA clone described by Malinowski et al. [9]. This extension does not contain a sequence known to function as a polyadenylation signal in eukaryotic mRNA [18]. A consensus AATAAA sequence is located at a position 46 nucleotides upstream of the polyadenylation site. The extension was further confirmed by sequencing using synthetic primers as indicated in figs 3 and 4. The coding region contains an amino-terminal sequence of 19 amino acids with the characteristics of a signal sequence [19].

The sequence for the mature protein shows the presence of an extra isoleucine at position 85 (fig.4) in comparison to the sequence published by Sottrup-Jensen et al. [5], giving a total of 791 amino acids for human plasminogen. The present cDNA sequence deviates from the published amino acid sequence at the following positions as also observed by Malinowski et al. [9]: Gln instead of Glu at position 342 and Asp instead of Asn at position 453 (fig.4). Beside these discrepancies, the cDNA sequence now obtained predicts Gln instead

of Glu at position 53 and Asn instead of Asp at position 88. The total amino acid composition of mature human plasminogen as well as the codon usage for the non-processed protein are given in tables 2 and 3, respectively. The calculated molecular mass for the processed non-glycosylated protein is 88400 Da, and for the heavy and the light chains 63200 and 25200 Da, respectively, as compared to an estimated 92 kDa for the glycosylated form and 57 and 25 kDa, respectively, for the heavy and light chains [20].

Table 2

Total amino acid composition of mature plasminogen
(the total number of amino acids is 791)

Amino acid	Number of residues	Mol%
Ala	36	4.55
Arg	42	5.31
Asn	39	4.93
Asp	36	4.55
Cys	48	6.07
Gln	30	3.79
Glu	54	6.83
Gly	60	7.59
His	23	2.91
Ile	22	2.78
Leu	42	5.31
Lys	48	6.07
Met	10	1.26
Phe	20	2.53
Pro	69	8.72
Ser	55	6.95
Thr	61	7.71
Trp	19	2.40
Tyr	30	3.79
Val	47	5.94

CCCCCCCCCCATGTAAGTCAACACATCTCGGATCGGACCCACTTCTGGGACTGCTGGCAGTCCCAAA MET
 ATG
 80
 GLU HIS LYS GLU VAL VAL LEU LEU LEU LEU LEU PHE LEU LYS SER GLY GLN GLY GLU PRO
 GAA CAT AAG GAA GTG GTT CTT CTA CTT CTT TTA TTT CTG AAA TCA GGT CAA GAA GAG CCT
 140
 LEU ASP ASP TYR VAL ASN THR GLN GLY ALA SER LEU PHE SER VAL THR LYS LYS GLN LEU
 CTG GAT GAC TAT GTG AAT ACC CAG GGG GCT CTA CTG TTC AGT GTC ACT AAG AAG CAG CTG
 200
 GLY ALA GLY SER ILE GLU GLU CYS ALA ALA LYS CYS GLU GLU ASP GLU GLU PHE THR CYS
 GGA GCA GGA AGT ATA GAA GAA TGT GCA GCA AAA TGT GAG GAG GAC GAA GAA TTC ACC TGC
 260
 ARG ALA PHE GLN TYR HIS SER LYS GLU GLN GLN CYS VAL ILE MET ALA GLU ASN ARG LYS
 AGG GCA TTC CAA TAT CAC AGT AAA GAG CAA CAA TGT GTG ATA ATG GCT GAA AAC AGG AAG
 320
 SER SER ILE ILE ILE ARG MET ARG ASP VAL VAL LEU PHE GLU LYS LYS VAL TYR LEU SER
 TCC TCC ATA ATC ATT AGG ATG AGA GAT GTA GTT TTA TTT GAA AAG AAA GTG TAT CTC TCA
 380
 GLU CYS LYS THR GLY ASN GLY LYS ASN TYR ARG GLY THR MET SER LYS THR LYS ASN GLY
 GAG TGC AAG ACT GGG AAT GGA AAG AAC TAC ACA GGG ACG ATG TCC AAA ACA AAA AAT GGC
 440
 ILE THR CYS GLN LYS TRP SER SER THR SER PRO HIS ARG PRO ARG PHE SER PRO ALA THR
 ATC ACC TGT CAA AAA TGG AGT TCC ACT TCT CCC CAC AGA CTT AGA TTC TCA CCT GCT ACA
 500
 HIS PRO SER GLU GLY LEU GLU GLU ASN TYR CYS ARG ASN PRO ASP ASN ASP PRO GLN GLY
 CAC CCC TCA GAG GGA CTG GAG GAG AAC TAC TGC AGG AAT CCA GAC AAC GAT CCG GAG GGG
 560
 PRO TRP CYS TYR THR THR ASP PRO GLU LYS ARG TYR ASP TYR CYS ASP ILE LEU GLU CYS
 CCC TGG TGG TAT ACT ACT GAT CCA GAA AAG AGA TAT GAC TAC TGC GAC ATT CTT GAG TGT
 620
 GLU GLU GLU CYS MET HIS CYS SER GLY GLU ASN TYR ASP GLY LYS ILE SER LYS THR MET
 GAA GAG GAA TGT ATG CAT TGC AGT GGA GAA AAC TAT GAC GGC AAA ATT TCC AAG ACC ATG
 680
 SER GLY LEU GLU CYS GLN ALA TRP ASP SER GLN SER PRO HIS ALA HIS GLY TYR ILE PRO
 TCT GGA CTG GAA TGC CAG GGC TGG GAC TCT CAG AGC CCA CAC GCT CAT GGA TAC ATT CCT
 740
 SER LYS PHE PRO ASN LYS ASN LEU LYS LYS ASN TYR CYS ARG ASN PRO ASP ARG GLU LEU
 TCC AAA TTT CCA AAC AAG AAC CTG AAG AAG AAT TAT TGT COT AAC CCC GAT AGG GAG CTG
 800
 ARG PRO TRP CYS PHE THR THR ASP PRO ASN LYS ARG TRP GLU LEU CYS ASP ILE PRO ARG
 CCG CCT TGG TGT TTC ACC ACC GAC CCC AAC AAG CCG TGG GAA CTT TGC GAC ATC CCC CGC
 860
 CYS THR THR PRO PRO PRO SER SER GLY PRO THR TYR GLN CYS LEU LYS GLY THR GLY GLU
 TGC ACA ACA CCT CCA CCA TCT COT GGT CCC ACC CAC TGT CTG AAG GAA ACA GGT GAA
 920
 ASN TYR ARG GLY ASN VAL ALA VAL THR VAL SER GLY HIS THR CYS GLN HIS TRP SER ALA
 AAC TAT CCG GGG AAT GTG GCT GTT ACC GTT TCC GGG CAC ACC TGT CAC CAC TGG AGT GCA
 980
 GLN THR PRO HIS THR HIS ASN ARG THR PRO GLU ASN PHE PRO CYS LYS ASN LEU ASP GLU
 CAG ACC CCT CAC ACA CAT AAC AGG ACA CCA GAA AAC TTC CCC TGC AAA AAT TGT GAT GAA
 1040
 ASN TYR CYS ARG ASN PRO ASP GLY LYS ARG ALA PRO TRP CYS HIS THR THR ASN SER GLN
 AAC TAC TGC CCG AAT CCT GAC GGA AAA AGG CCC CCA TGG TGC CAT ACA ACC AAC AGC CAA
 1100
 VAL ARG TRP GLU TYR CYS LYS ILE PRO SER CYS ASP SER SER PRO VAL SER THR GLU GLN
 GTG CCG TGG GAG TAC TGT AAG ATA CCG TCC TGT GAC TCC CCA GTA TCC ACG GAA CAA
 1160
 LEU ALA PRO THR ALA PRO PRO GLU LEU THR PRO VAL VAL GLN ASP CYS TYR HIS GLY ASP
 TTG GCT CCC ACA GCA CCA CCT GAG CTA ACC CCT GTG GTC CAG GAC TGC TAC CAT GAT GAT
 1220
 GLY GLN SER TYR ARG GLY THR SER SER THR THR THR THR GLY LYS LYS CYS GLN SER TRP
 GGA CAG AGC TAC CCA GGC ACA TCC TCC ACC ACC ACC ACA GGA AAG AAG TGT CAG TCT TGG
 1280
 SER SER MET THR PRO HIS ARG HIS GLN LYS THR PRO GLU ASN TYR PRO ASN ALA GLY LEU
 TCA TCT ATG ACA CCA CAC CCG CAC CAG AAG ACC CCA GAA AAC TAC CCA AAT GCT GGC CTG
 1340
 THR MET ASN TYR CYS ARG ASN PRO ASP ALA ASP LYS GLY PRO TRP CYS PHE THR THR ASP
 ACA ATG AAC TAC TGC AGG AAT CCA GAT GCC GAT AAA GGC CCC TGG TGT TTT ACC ACA GAC
 1400
 PRO SER VAL ARG TRP GLU TYR CYS ASN LEU LYS LYS CYS SER GLY THR GLU ALA SER VAL
 CCC AGC GTC AGG TGG GAG TAC TGC AAG CAG AAA AAC TGC TCA GGA ACA GAA GCG AGT GTT
 1460
 VAL ALA PRO PRO PRO VAL VAL LEU LEU PRO ASP VAL BLU THR PRO SER BLU BLU ASP CYS
 GTA GCA CCT CCG CCT GTT GTC CTG CTT CCA GAT GTA GAG ACT CCT TCC GAA GAA GAC TGT
 1520
 MET PHE GLY ASN GLY LYS GLY TYR ARG GLY LYS ARG ALA THR THR VAL THR GLY THR PRO
 ATG TTT GGG AAT GGG AAA GAA TAC CAA GGC AAG AGG GCG ACC ACT GTT ACT GGG ACG CCA

1580
 CYS GLN ASP TRP ALA ALA GLN GLU PRO HIS ARG HIS SER ILE PHE THR PRO GLU THR ASN
 TGC CAG GAC TGG GCT GCG CAG GAG CCC CAT AGA CAC ABC ATT TTC ACT CCA GAG ACA AAT
 1640
 PRO ARG ALA GLY LEU GLU LYS ASN TYR CYS ARG ASN PRO ASP GLY ASP VAL GLY GLY PRO
 CCA CCG GCG GGT CTG GAA AAA AAT TAC TGC CGT AAC CCT GAT GGT GAT GTA GGT GGT CCC
 1700
 TRP CYS TYR THR THR ASN PRO ARG LYS LEU TYR ASP TYR CYS ASP VAL PRO GLN CYS ALA
 TGG TGC TAC ACG ACA AAT CCA AGA AAA CTT TAC GAC TAC TGT GAT GTC CCT CAG TGT GCG
 1760
 ALA PRO SER PHE ASP CYS GLY LYS PRO GLN VAL GLU PRO LYS LYS CYS PRO GLY ARG VAL
 GCC CCT TCA TTT GAT TGT GGG AAG CCT CAA GTG GAG CCG AAG AAA TGT CCT GGA AGG GTT
 1820
 VAL GLY GLY CYS VAL ALA HIS PRO HIS SER TRP PRO TRP GLN VAL SER LEU ARG THR ARG
 GTG GGG GGG TGT GTG GCC CAC CCA CAT TCC TGG CCC TGG CAA GTC AGT CTT AGA ACA AGG
 1880
 PHE GLY MET HIS PHE CYS GLY GLY THR LEU ILE SER PRO GLU TRP VAL LEU THR ALA ALA
 TTT GGA ATG CAC TTC TGT GGA GGC ACC TTG ATA TCC CCA GAG TGG GTG TTG ACT GCT GCG
 1940
 HIS CYS LEU GLU LYS SER PRO ARG PRO SER SER TYR LYS VAL ILE LEU GLY ALA HIS GLN
 CAC TGC TTG GAG AAG TCC CCA AGG CCT TCA TCC TAC AAG GTC ATC CTG GGT GCA CAC GAA
 2000
 GLU VAL ASN LEU GLU PRO HIS VAL GLN GLU ILE GLU VAL SER ARG LEU PHE LEU GLU PRO
 GAA GTG AAT CTT CCA CCG CAT GTT CAG GAA ATA GAA GTG TCT AGG CTG TTC TTG GAG CCC
 2060
 THR ARG LYS ASP ILE ALA LEU LEU LYS LEU SER SER PRO ALA VAL ILE THR ASP LYS VAL
 ACA GGA AAA GAT ATT GCC TTG CTA AAG CTA AGC AGT GCT GCC GTC ATC ACT GAC AAA GTA
 2120
 ILE PRO ALA CYS LEU PRO SER PRO ASN TYR VAL VAL ALA ASP ARG THR GLU CYS PHE ILE
 ATC CCA GCT TGT CTG CCA TCC CCA AAT TAT GTG GTC GCT GAC CCG ACC GAA TGT TTC ATC
 2180
 THR GLY TRP GLY GLU THR GLN GLY THR PHE GLY ALA GLY LEU LEU LYS GLU ALA GLN LEU
 ACT GGC TGG GGA GAA ACC CAA GGT ACT TTT GGA GCT GGC CTT CTC AAG GAA GCC CAG CTC
 2240
 PRO VAL ILE GLU ASN LYS VAL CYS ASN ARG TYR GLU PHE LEU ASN GLY ARG VAL GLN SER
 CCT GTG ATT GAG AAT AAA GTG TGC AAT CCG TAT GAG TTT CTG AAT GGA AGA GTC CAA TCC
 2300
 THR GLU LEU CYS ALA GLY HIS LEU ALA GLY GLY THR ASP SER CYS GLN GLY ASP SER GLY
 ACC GAA CTC TGT GCT GGG CAT TTG GCC GGA GGC ACT GAC AGT TGC CAG GGT GAC AGT GGA
 2360
 GLY PRO LEU VAL CYS PHE GLU LYS ASP LYS TYR ILE LEU GLN GLY VAL THR SER TRP GLY
 GGT CCT CTG GTT TGC TTC GAG AAG GAC AAA TAC ATT TTA CAA GGA GTC ACT TCT TGG GGT
 2420
 LEU GLY CYS ALA ARG PRO ASN LYS PRO GLY VAL TYR VAL ARG VAL SER ARG PHE VAL THR
 CTT GGC TGT GCA CCG CCC AAT AAG CCT GGT GTC TAT GTT GGT GAT TCA AGG TTT GTT ACT
 2480
 TRP ILE GLU GLY VAL MET ARG ASN ASN TTT TGGACGGGACAGAGTACGACACTGACTCACCTAGAG
 TGG ATT GAG GGA GTG ATG AGA AAT AAT TAA
 2549
 GCTGGGACGCTGGTAGGGATTAGCATGCTGGAAATACTGGCAGTAATCAACGAGACACTGTCCCGAGCTACCACT
 2629
 ACGCCAAACCTCGGCATTTTGTGTATTTCTGACTGCTGGATTTCTGTAGTAAGGTGACATGCTATGACATTTGTTA
 2789
 AAGATTAAGCTCTGTACTTAACITTTGATTTGAGTAATTTTGGTTTGGTCTTCAACAAAAA~~~~~
 ~~~~~~




Fig.4. cDNA sequence for pPLGKG. The arrows  and  indicate the start of the mature protein and the site of cleavage of the proenzyme, respectively. Boxed amino acids represent amino acid deviations in comparison to the published amino acid sequence [5]. Underlining in the coding region of the DNA sequence indicates the segment used for preparation of the oligonucleotide probe.  represents synthetic oligonucleotide primers. In the 3'-non-coding region, the consensus polyadenylation site is underlined.

Table 3

Codon usage for human plasminogen including the signal sequence

Total number of amino acids 811

| Phe |    | Ser |    | Tyr  |    | Cys  |    |
|-----|----|-----|----|------|----|------|----|
| TTT | 10 | TCT | 9  | TAT  | 10 | TCT  | 25 |
| TTC | 11 | TCC | 20 | TAC  | 20 | TGC  | 23 |
| Leu |    | TCA | 10 | Stop |    | Stop |    |
| TTA | 3  | TCG | 0  | TAA  | 1  | TGA  | 0  |
| TTG | 8  |     |    | TAG  | 0  | Trp  |    |
|     |    |     |    |      |    | TGG  | 19 |
| Leu |    | Pro |    | His  |    | Arg  |    |
| CTT | 10 | CCT | 23 | CAT  | 10 | CGT  | 3  |
| CTC | 5  | CCC | 16 | CAC  | 14 | CGC  | 6  |
| CTA | 4  | CCA | 25 | Gln  |    | CGA  | 3  |
| CTG | 18 | CCG | 5  | CAA  | 13 | CGG  | 5  |
|     |    |     |    | CAG  | 18 |      |    |
| Ile |    | Thr |    | Asn  |    | Ser  |    |
| ATT | 9  | ACT | 16 | AAT  | 22 | AGT  | 11 |
| ATC | 7  | ACC | 22 | AAC  | 18 | AGC  | 6  |
| ATA | 6  | ACA | 19 | Lys  |    | Arg  |    |
| Met |    | ACG | 4  | AAA  | 22 | AGA  | 10 |
| ATG | 11 |     |    | AAG  | 27 | AGG  | 15 |
| Val |    | Ala |    | Asp  |    | Gly  |    |
| GTT | 13 | GCT | 13 | GAT  | 15 | GGT  | 14 |
| GTC | 12 | GCC | 11 | GAC  | 21 | GGC  | 11 |
| GTA | 6  | GCA | 9  | Glu  |    | GGA  | 24 |
| GTG | 17 | GCG | 4  | GAA  | 31 | GGG  | 13 |
|     |    |     |    | GAG  | 25 |      |    |

#### 4. DISCUSSION

The amino acid sequence for human plasminogen predicted from the nucleotide sequence now presented shows the following discrepancies, besides those reported by Malinowski et al. [9], when compared to the sequence published by Sottrup-Jensen et al. [5]: an extra Ile in the amino-terminal region of the mature protein, a Gln at position 53 instead of Glu, and Asn at position 88 instead of the reported Asp. The presence of the extra isoleucine residue can be explained by polymorphism or more likely by being overlooked in the protein sequencing since complete liberation of isoleucine, upon

hydrolysis, can require extensive hydrolysis. All other deviations in the amino acid sequence are most likely due to difficulties in assignments of amidated or non-amidated forms of the amino acids in the protein sequence. However, in view of recent work [21] a polymorphism cannot be ruled out. The NMR studies on kringle 1 of human plasminogen which suggest discrepancies in the number of methionine, phenylalanine, tyrosine, and histidine residues [20] cannot be confirmed from the predicted amino acid sequence of the cDNA clone now isolated. For detection of any heterogeneity, in kringle 1 due to allelic variations, further analysis of cDNA clones from more human individuals are required in order for this to be determined. The now presented amino acid sequence therefore essentially confirms the sequence presented by Sottrup-Jensen et al. [5].

Unlike many plasma proteins synthesized in the liver, human plasminogen does not seem to be synthesized with a pre-pro leader sequence. It is unlikely that the nucleotide sequence (fig.4) does not represent a full-length clone. The signal sequence predicted from the DNA sequence is a strong argument for the presence of a full-length clone.

The discrepancy in molecular mass found for the heavy chain is most likely due to the absence of the activation peptide in the heavy chain reported to have a molecular mass of 57 kDa. The overall codon usage is fairly random except that one codon, TCG for Ser, is not used at all.

A polyadenylation signal (AATAAA) is generally found within 6–26 bases before the polyadenylation site in most eukaryotic genes characterized so far [18]. Compared to the partial plasminogen cDNA described by Malinowski et al. [9] our clone contains an additional 29 bases at the 3'-end. No typical polyadenylation sequence is contained within these 29 bases. The consensus polyadenylation sequence AATAAA is thus located 46 bases upstream from the poly-A tail. A variation in the length of the 3'-non-coding region has been found previously, e.g. in cDNA clones corresponding to the  $\beta$ -subunit of alcohol dehydrogenase which were isolated from the same cDNA library [22].

Sadler et al. [23] have presented a partial genomic organization of kringles 4 and 5, and part of the light chain in human plasminogen. The cDNA clone for human plasminogen now

presented will facilitate isolation of genomic clones for a further characterization of the genomic organization of the human gene for plasminogen and its evolutionary relationship to other serine proteases.

## ACKNOWLEDGEMENTS

We would like to thank Hans Jornvall and Lars Rutberg for valuable comments. This work was supported by KabiGen AB.

## REFERENCES

- [1] Robbins, K.C. (1982) in: Hemostasis and Thrombosis (Colman, R.W. et al. eds) pp.623–639, J.B. Lippincott, Philadelphia.
- [2] Wiman, B. and Wallen, P. (1975) *Eur. J. Biochem.* 50, 489–494.
- [3] Wiman, B. and Wallen, P. (1975) *Eur. J. Biochem.* 58, 539–547.
- [4] Wiman, B. (1977) *Eur. J. Biochem.* 76, 129–137.
- [5] Sottrup-Jensen, L., Petersen, T.E. and Magnusson, S. (1978) in: Atlas of Protein Sequence and Structure (Dayhoff, M.O. ed.) vol.5, suppl.3, p.91, National Biomedical Research Foundation, Silver Spring, MD.
- [6] Robbins, K.C., Summaria, L., Hsich, B. and Shah, R.J. (1967) *J. Biol. Chem.* 242, 2333–2342.
- [7] Patthy, L. (1985) *Cell* 41, 657–663.
- [8] Patthy, L., Trexler, M., Vali, Z., Banyai, L. and Varadi, A. (1984) *FEBS Lett.* 171, 131–136.
- [9] Malinowski, D.P., Sadler, J.E. and Davie, E.W. (1984) *Biochemistry* 23, 4243–4250.
- [10] Okayama, H. and Berg, P. (1982) *Mol. Cell. Biol.* 2, 161–170.
- [11] Okayama, H. and Berg, P. (1983) *Mol. Cell. Biol.* 3, 280–289.
- [12] Josephson, S., Lagerholm, E. and Palm, G. (1984) *Acta Chem. Scand.* B38, 539–545.
- [13] Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982) *Molecular Cloning. A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- [14] Holmes, D.S. and Quigley, M. (1981) *Anal. Biochem.* 114, 193–197.
- [15] Sanger, S., Nicklen, S. and Coulson, A.R. (1977) *Proc. Natl. Acad. Sci. USA* 74, 5463–5467.
- [16] Crouse, G.F., Frischauf, A. and Lehrach, H. (1983) *Methods Enzymol.* 101, 78–89.
- [17] Kozak, M. (1983) *Microbiol. Rev.* 47, 1–45.
- [18] Wickens, M. and Stephenson, P. (1984) *Science* 226, 1045–1051.
- [19] Von Heijne, G. (1983) *Eur. J. Biochem.* 133, 17–21.
- [20] De Marco, A., Hochschwender, S.M., Laursen, R.A. and Llinas, M. (1982) *J. Biol. Chem.* 257, 12716–12721.
- [21] Nishimukai, H., Shinmyozu, K. and Tamaki, Y. (1986) *Hum. Hered.* 36, 137–142.
- [22] Hedén, L.-O., Hoog, J.-O., Larsson, K., Lake, M., Lagerholm, E., Holmgren, A., Vallee, B.L., Jornvall, H. and Von Bahr-Lindstrom, H. (1986) *FEBS Lett.* 194, 327–332.
- [23] Sadler, J.E., Malinowski, D.P. and Davie, E.W. (1985) in: *Progress in Fibrinolysis VII* (Davidson, J.F. et al. eds) pp.201–204, Churchill Livingstone, Edinburgh.